Alumis (ALMS) had its price target raised by Morgan Stanley from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Alumis (ALMS) had its price target raised by Chardan Capital from $37.00 to $38.00. They now have a "buy" rating on the stock.
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]